ACMJ

Anatolian Current Medical Journal (ACMJ) is an unbiased, peer-reviewed, and open access international medical journal. The Journal publishes interesting clinical and experimental research conducted in all fields of medicine, interesting case reports, and clinical images, invited reviews, editorials, letters, comments, and related knowledge.

EndNote Style
Index
Original Article
Exploring the nexus: prevalence, risk factors, and clinical correlations of urinary tract infections in diabetes mellitus patients - a comprehensive retrospective analysis
Aims: This study investigates the frequency and associated factors of urinary tract infections (UTIs) in patients with diabetes mellitus (DM).
Methods: This retrospective chart review focused on patients with diabetes mellitus. Data collection involved demographic details, DM diagnosis, comorbidities such as hypertension, hyperlipidemia, and coronary artery disease, along with medication usage. Laboratory values including blood glucose and HbA1c levels were also analyzed. The primary outcome of interest was the diagnosis of UTI, identified from clinical records.
Results: 173 DM patients were included in the study. These patients were divided into two groups according to the presence of UTI: 52 patients in the UTI group and 121 patients in the non-UTI group. The incidence of UTI was significantly higher in women (37.9%) compared to men (10.2%). No significant differences were observed between the groups in terms of age, presence of hypertension, hyperlipidemia, or coronary artery disease. Interestingly, the usage of SGLT-2 inhibitors was significantly higher in the UTI group compared to the non-UTI group (26.8% vs. 14%, p=0.043). No significant differences were found in other medication usage or in the levels of glucose and HbA1c between the groups.
Conclusion: The study highlights the increased risk of UTIs in DM patients, particularly among women and those using SGLT-2 inhibitors. These findings suggest the need for careful monitoring and tailored approaches in managing UTIs in DM patients, considering gender and specific DM treatments.


1. Hsia DS, Grove O, Cefalu WT. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus.Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-79.
2. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs andgenital infections in type 2 diabetes mellitus: a systematic reviewand meta-analysis. Sci Rep. 2017;7(1):2824.
3. Geerlings SE, Brouwer EC, Gaastra W, Verhoef J, Hoepelman AIM.Effect of glucose and pH on uropathogenic and non-uropathogenicEscherichia coli: studies with urine from diabetic and non-diabeticindividuals. J Med Microbiol. 1999;48(6):535-539.
4. Petersmann A, Müller-Wieland D, Müller UA, et al. Definition,classification and diagnosis of diabetes mellitus. Exp ClinEndocrinol Diabetes. 2019;127:S1-S7.
5. Lovic D, Piperidou A, Zografou I, Grassos H, Pittaras A,Manolis A. The growing epidemic of diabetes mellitus. Curr VascPharmacol. 2020;18(2):104-109.
6. Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiologyof type 2 dia- betes mellitus and its complications. Nat RevEndocrinol. 2018;14:88-98.
7. Faselis C, Katsimardou A, Imprialos K, Deligkaris P, KallistratosM, Dimitriadis K. Microvascular complications of type 2 diabetesmellitus. Curr Vasc Pharmacol. 2020;18(2):117-124.
8. Cloete L. Diabetes mellitus: an overview of the types, symptoms,complications and management. Nurs Stand. 2022;37(1):61-66.
9. Gupta K, Sahm DF, Mayfield D, Stamm WE. Antimicrobialresistance among uropathogens that cause community acquiredurinary tract infections in women: a nationwide analysis. ClinInfect Dis. 2001;33(1):89-94.
10. Carrondo MC, Moita JJ. Potentially preventable urinary tractinfection in patients with type 2 diabetes—a hospital-basedstudy. Obes Med. 2020;17:100190.
11. Kamei J, Yamamoto S. Complicated urinary tract infections withdiabetes mellitus. J Infect Chemother. 2021;27(8):1131-1136.
12. Al Qurabiy HE, Abbas IM, Hammadi AA, Mohsen FK, SalmanRI, Dilfy SH. Urinary tract infection in patients with diabetesmellitus and the role of parental genetics in the emergence of thedisease. J Med Life. 2022;15(8):955-962.
13. Berbudi A, Rahmadika N, Tjahjadi AI, Ruslami R. Type 2diabetes and its impact on the immune system. Curr DiabetesRev. 2020;16(5):442-449.
14. Nitzan O, Elias M, Chazan B, Saliba W. Urinary tract infectionsin patients with type 2 diabetes mellitus: review of prevalence,diagnosis, and man- agement. Diabetes Metab Syndr Obes.2015;8:129-136.
15. Gorter KJ, Hak E, Zuithoff NP, Hoepelman AI, Rutten GE. Riskof recurrent acute lower urinary tract infections and prescriptionpattern of antibiot- ics in women with and without diabetes inprimary care. Fam Pract. 2010;27(4):379-385.
16. Zheng Z, He D, Chen J, et al. Risk of urinary tract infection inpatients with type 2 diabetes mellitus treated with dapagliflozin:a systematic review and meta-analysis of randomized controlledtrials. Clin Drug Investig. 2023;43(4):209-225.
17. Puckrin R, Saltiel MP, Reynier P, Azoulay L, Yu OHY, Filion KB.SGLT-2 inhibitors and the risk of infections: a systematic reviewand meta-analysis of randomized controlled trials. Acta Diabetol.2018;55(5):503-514.
18. Merész G, Szabó S, Dóczy V, Hölgyesi Á, Szakács Z. A húgyútifertozések relatív gyakorisága metforminnal és SGLT2-gátlóvalkezelt 2-es típusú diabetes mellitusban szenvedo betegekben.Hálózati metaanalízis. Orv Hetil. 2020;161(13):491-501.
19. Bodke H, Wagh V, Kakar G. Diabetes mellitus and prevalenceof other comorbid conditions: a systematic review. Cureus.2023;15(11):e49374.
20. Liu F, Ling Z, Xiao Y, et al. Alterations of urinary microbiotain type 2 diabetes mellitus with hypertension and/orhyperlipidemia. Front Physiol. 2017;8:126. doi:10.3389/fphys.2017.00126
Volume 6, Issue 1, 2024
Page : 93-96
_Footer